Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 2, 2007, Pages 269-274

  Seo, Jae Hong ^a   Oh, Sang Cheul ^a   Choi, Cheul Won ^a   Kim, Byung Soo ^a   Shin, Sang Won ^a   Kim, Yeul Hong ^a   Kim, Jun Suk ^a   Kim, Ae Ree ^b   Lee, Jae Bok ^b   Koo, Bum Hwan ^b  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Cisplatin; Gemcitabine; Metastatic breast cancer; Taxane resistant

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LEUCOGEN; METOCLOPRAMIDE; NAVELBINE; TAXANE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DEATH; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPHIL COUNT; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REPEATED DRUG DOSE; SALVAGE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ALOPECIA; ANEMIA; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOPENIA; MIDDLE AGED; NEOPLASM METASTASIS; RECURRENCE; SEVERITY OF ILLNESS INDEX; STOMATITIS; SURVIVAL RATE; TAXOIDS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 33845357272     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0266-x     Document Type: Article

References (28)

1. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197-2205
2. Merriman RL, Hertel LW, Schultz RM, Houghton PJ, Houghton JA, Rutherford PG, et al (1996) Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs 14:243-247
3. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA (1994) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12:1535-1540
4. Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJ, et al (1996) Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 32:243-248
5. Seidman AD (2001) The evolving role of gemcitabine in the management of breast cancer. Oncology 60:189-198
6. Kolaric K, Roth A (1983) Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 11:108-112
7. Mechl Z, Sopkova B (1984) CAP (cyclophosphamide, adriamycin, cisplatin in the treatment of advanced breast cancer. Neoplasma 31:431-435
8. Sledge GW Jr, Loehrer PJ Sr, Roth BJ, Einhorn LH (1988) Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 6:1811-1814
9. Bajorin D, Bosl GJ, Fein R (1987) Phase I trial of escalating doses of cisplatin in hypertonic saline. J Clin Oncol 5:1589-1593
10. Forastiere AA, Hakes TB, Wittes JT, Wittes RE (1982) Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules. Am J Clin Oncol 5:243-247
11. Martino S, Samal BA, Singhakowinta A, Yoshida S, Mackenzie M, Jain J et al (1984) A phase II study of cis-diamminedichloroplatinum II for advanced breast cancer. Two dose schedules. J Cancer Res Clin Oncol 108:354-356
12. Ostrow S, Egorin M, Aisner J, Bachur N, Wiernik PH (1980) High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. Cancer Clin Trials 3:23-27
13. Ramnath N, LoRusso P, Simon M, Martino S (1997) Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer. Am J Clin Oncol 20:368-372
14. Yap HY, Salem P, Hortobagyi GN, Bodey GP Sr, Buzdar AU, Tashima CK et al (1978) Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. Cancer Treat Rep 62:405-408
15. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ (1994) Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines. Adv Exp Med Biol 370:139-143
16. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ (1996) Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2:521-530
17. Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ (1995) Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin Oncol 22:72-79
18. Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS (2000) Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol 18:2245-2249
19. Heinemann V, Stemmler HJ, Wohlrab A, Bosse D, Losem C, Kahlert S, et al (2005) High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer. Cancer chemother Pharmacol 15:1-7
20. Mohran TZ (2004) Gemcitabine and Cisplatin combination chemotherapy as a first-line treatment in patients with metastatic breast cancer. J Egypt Natl Canc Inst 16:8-14
21. Verma S, Trudeau M, Dranitsaris G, Clemons M, Joy AA, MacKey JR (2005) What is the best chemotherapy treatment option for anthracycline and taxane pretreated metastatic breast cancer? J Clin Oncol 23:6260
22. Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, et al (2004) Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 22:3893-3901
23. Frasci G, D'Aiuto G, Comella P, Thomas R, Capasso I, Botti G, et al (2001) Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline- and taxanerefractory breast cancer patients: a southern Italy cooperative oncology group phase I/II study. Semin Oncol 28:50-56
24. Schmid P, Heilmann V, Schulz CO, Dieing A, Lehenbauer-Dehm S, Jehn C et al (2005) Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study. J Cancer Res Clin Oncol 131:568-574
25. Smorenburg CH, Bontenbal M, Seynaeve C, van Zuylen C, de Heus G, Verweij J et al (2001) Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 66:83-87
26. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339:900-905
27. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, et al (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122-130
28. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ et al (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077